Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech ...

The main treaties placing limits on methods and means of waging war are the Hague Conventions of 1907, the 1977 Additional Protocols to the Geneva Conventions and a series of agreements on specific ...

Angion Biomedica (NASDAQ: ANGN) will be changing to (NASDAQ: ELTX) at the open this morning. This is all a part of the merger with Elicio Therapeutics from January - with an assist from a little stock ...

Angion Biomedica Corp. ANGN announced that it has entered into a definitive merger agreement with the privately-held biotech, Elicio Therapeutics, wherein the latter will merge with a wholly-owned ...

Information about Angion's directors and executive officers is included in Angion's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 30, 2022, and the proxy ...

In a merger with troubled Angion Biomedica, Elicio Therapeutics has spied an opportunity to finally list on the Nasdaq as it prepares to push a cancer vaccine into phase 2 trials. The writing had been ...

Elicio Therapeutics, a clinical-stage biotech, is merging with Angion Biomedica Corp to form a company that will focus on immunotherapies using Elicio’s proprietary lymph node-targeting Amphiphile ...

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small ...

Angion Biomedica beat estimated earnings by 34.78%, reporting an EPS of $-0.3 versus an estimate of $-0.46. Revenue was up $113 thousand from the same period last year. Last quarter the company missed ...

The setbacks keep coming at Angion Biomedica. Having failed two clinical trials last year, the biotech has now stopped a third study after identifying a potential safety signal that triggered a ...

Angion Biomedica missed estimated earnings by 11.63%, reporting an EPS of $-0.48 versus an estimate of $-0.43. Revenue was up $1.28 million from the same period last year. Last quarter the company ...